TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05286268

Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia Modified Albumin
Description: Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia Modified Albumin
Description: Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system.
Study: NCT06248801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Metformin-Test product
Description: Vildagliptin and Metformin tablets 50/1000 mg manufactured by Mylan Laboratories Limited, India

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Metformin-Reference product
Description: Vildagliptin and Metformin tablets 50/1000 mg manufactured by NOVARTIS PHARMA PRODUKTIONS GmbH, Germany.
Study: NCT06373627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A hypnosis session takes place in 3 stages:~* An induction stage, where we move from an ordinary state of consciousness to a modified state of consciousness through dissociation.~* A work phase to deepen the hypnotic trance. This phase is fueled by the construction of suggestions and metaphors, analogous to those of the patient in pain.~* Finally, a return to the ordinary state of consciousness through re-association with the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medications used for sedation-analgesia
Description: MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications used in addition to hypnosis
Description: MEOPA + intravenous ketamine (0.3 mg/kg)
Study: NCT06385639

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
Study: NCT05557006

Intervention type: PROCEDURE
Intervention: left bundle branch pacing
Description: In the procedure of left bundle branch pacing, various QRS morphologies are observed as penetrating the lead into the interventricular septum.
Study: NCT04840433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MACE
Description: Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
Study: NCT05160662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New guidlines
Description: New guidelines for this group are being developed using NICE guidelines (evidence-based recommendations for health and care in England) as a model and will be tested in clinical practice
Study: NCT05437653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Drink A
Description: 300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Drink A
Description: 300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
Study: NCT05036356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headspace App
Description: A mobile-application (app) focusing on teaching and sustaining mental well-being.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headspace App
Description: A mobile-application (app) focusing on teaching and sustaining mental well-being.
Study: NCT05437653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Drink B
Description: 300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Drink B
Description: 300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
Study: NCT06673511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node visualization
Description: Resect the developing lymph nodes and the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No visualization of lymph nodes
Description: Resect the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
Study: NCT05361733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XFB-19
Description: XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient drug use to blind participants and investigators
Study: NCT05537493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: It will be followed by exercising on whatsapp

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to face
Description: It will be followed by face to face
Study: NCT05476913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko™ device
Description: Neuromuscular electrical stimulation of the peroneal nerve
Study: NCT05107388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro
Description: Measurements of interstitial glucose variations with FreeStyle Libre Pro
Study: NCT04857892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254/DTG
Description: GSK3640254/DTG will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254/DTG
Description: GSK3640254/DTG will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254/DTG
Description: GSK3640254/DTG will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254/DTG
Description: GSK3640254/DTG will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254/DTG
Description: GSK3640254/DTG will be administered via oral route.
Study: NCT06385639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
Study: NCT06445062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet
Study: NCT05241665

Intervention type: DEVICE
Intervention: SpectraWAVE Imaging System
Description: Coronary imaging

Intervention type: DEVICE
Intervention: SpectraWAVE Imaging System
Description: Coronary imaging
Study: NCT06445062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: IV infusion
Study: NCT06391567

Intervention type: OTHER
Intervention: There was no intervention in this study.
Description: There was no intervention in this study.
Study: NCT05955105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB-2109
Description: ILB-2109 tablets will be administered by mouth every day in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab injection will be administered via IV every 21 days.
Study: NCT05135117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroRescue Cooling Collar
Description: Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Towel
Description: Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
Study: NCT05664555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium
Description: Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein Sodium
Description: Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
Study: NCT06445062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX regimen
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX regimen
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV infusion
Study: NCT05379205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation program (4 week before the surgery)
Description: This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative program (12 week after the surgery)
Description: This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.~NOTE: Both preoperative and postoperative programs will be administer to the participants assigned to the intervention group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care group will follow the usual institutional pre-surgery care: (i) medication management, (ii) assessment of the surgery-derived risks, (iii) smoking cessation and peri-operative blood management. A trained nutritionist will evaluate the nutritional status of all patients at the baseline providing oral protein/vitamin supplementation, when necessary. Patients allocated to the control group will receive basic expert' advice on lifestyle changes.
Study: NCT06383819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Longidaza®
Description: dose 3000 IU intramuscularly once every 5 days, 15 injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscularly once every 5 days, 15 injections
Study: NCT05401903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Maintenance Care
Description: Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study.
Study: NCT05666908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO
Description: After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) \> 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
Study: NCT05380960

Intervention type: DEVICE
Intervention: cbc coaglation profile
Description: The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).

Intervention type: DEVICE
Intervention: cbc coaglation profile
Description: The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).

Intervention type: DEVICE
Intervention: cbc coaglation profile
Description: The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
Study: NCT06430645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.3mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.6mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). The same volume of 0.9% saline instead of esketamine will be given to the control group after stable plasma concentration of propofol deep sedation.
Study: NCT06451276

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasoalveolar molding in unilateral cleft lip and palate
Description: compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding in unilateral cleft lip and palate
Description: compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate
Study: NCT06343454

Intervention type: OTHER
Group type: OTHER
Intervention: Digital Interocclusal Record In Different Head Positions
Description: Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner
Study: NCT06445062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-9805
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-9805
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-9805
Description: Oral Tablet
Study: NCT06343454

Intervention type: OTHER
Group type: OTHER
Intervention: Digital Interocclusal Record In Different Head Positions
Description: Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner

Intervention type: OTHER
Group type: OTHER
Intervention: Digital Interocclusal Record In Different Head Positions
Description: Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner
Study: NCT04966273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcatheter
Description: Only to be used if Biosensor Microcatheter does not perform accordingly
Study: NCT04647721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant (dermal filler)
Description: Subdermal injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant (dermal filler)
Description: Subdermal injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane injectable implant (dermal filler)
Description: Subdermal injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane injectable implant (dermal filler)
Description: Subdermal injection.
Study: NCT05865730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Bacterial Product - Akkermansia muciniphila
Description: Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Bacterial Product - Akkermansia muciniphila
Description: Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.